Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Find the latest information on COVID-19, monkeypox, and the flu vaccine

Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting Lim, M., Weller, M., Chiocca, E. A. 2016; 35: e132–9

Abstract

Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed.

View details for DOI 10.14694/EDBK_159084

View details for PubMedID 27249715